🔗 Share this article

As the United States continues making sweeping adjustments to its immunization schedules, one figure appears unexpectedly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning COVID-19 shots during the global health crisis and has zeroed in on possible fatalities following Covid vaccination in her recent position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Schedule

Public health authorities had intended to reveal sweeping changes to the pediatric vaccine schedule in December, bringing the US with the Danish immunization schedule, it is understood – a major change that would put the US at odds with many the global community with little proof for public health gain. The announcement has been postponed until the new year.

In place of Vinay Prasad, Høeg is listed to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this calendar year.

A New Direction at the FDA

The acting appointment could signify a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some childhood shot schedules in the US in order to be more similar to Denmark's approach, a country with comprehensive healthcare and a population approximately the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Expertise

The appointee has little discernible background in drug development, approval processes or administrative roles, which has been customary for previous leaders of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a large organization. She has no expertise in industry regulation.”

Former directors of CBER would “grasp laws and regulations and the research of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who ran the center have had.”

This division has an vast workload at the agency, Woodcock pointed out.

“Many people just pays attention on the innovative therapies, but the off-patent medication office clears numerous off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and so forth, and all of those have to be managed,” she explained. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a significant leadership component to the role, which supervises more than 5,000 employees. “It’s a massive management job, if you execute it properly,” she said.

Agency Reaction and Disputed Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment indicates greater collaboration among FDA leaders on immunizations, a spokesperson said that the “inquiries are based on flawed assumptions”.

“Her resume matches the responsibilities of her role,” the spokesperson explained, citing the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the commissioner’s controversial expedited review system, a controversial expedited drug-approval program that reportedly troubled her preceding directors. “How are these drugs being selected for this voucher program? Who is making the calls?” Dr. Howard said. “There’s a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the agency seems to be moving towards laxer rules of all drugs, aside from immunizations.”

Established History on Vaccines

With vaccines, Dr. Høeg has a clearer, if problematic, track record, Howard said. She released a analysis using unconfirmed crowd-sourced reports to assess the rate of myocarditis after COVID-19 immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are riskier than they are.

Part of her “wish list” for the new federal leadership featured changing guidelines for novel immunizations and discontinuing “optional” vaccines, she said following the vote on a podcast. At the agency, Høeg has reportedly suggested barring young men from obtaining COVID-19 vaccines.

“She is an complete dogmatist who begins with her preconceived notions and reverse-engineers to fit the evidence in a very disingenuous, dishonest manner,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|